智通财经APP讯，玮俊生物科技(00660)发布公告，由于公司及核数师需要额外时间完成审计工作，公司无法根据上市规则第13.49(1)条的规定，于2026年9月30日或之前刊发2026年度业绩。公司正与核数师紧密合作，为尽快完成审计工作程序而提供一切必要资料及文件，惟将需要进一步与核数师讨论及确定年度业绩的预计发布日期，并将适时作出公布。
根据上市规则第13.50条，倘发行人未能根据上市规则刊发定期财务资料，香港联交所通常会要求暂停发行人证券的买卖，而暂停买卖通常会持续至发行人刊发载有所需财务资料的公布为止。
根据上市规则，倘2026年度业绩未能于2026年9月30日前刊发，预期公司股份将于联交所暂停买卖，自该限期后下一个营业日(即2026年10月2日)上午9时正起生效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.